Parkside Financial Bank & Trust Acquires 759 Shares of Becton, Dickinson and Company $BDX

Parkside Financial Bank & Trust raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 64.1% during the 2nd quarter, Holdings Channel reports. The fund owned 1,943 shares of the medical instruments supplier’s stock after purchasing an additional 759 shares during the period. Parkside Financial Bank & Trust’s holdings in Becton, Dickinson and Company were worth $335,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Saudi Central Bank bought a new stake in Becton, Dickinson and Company during the first quarter valued at about $26,000. Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at about $31,000. WPG Advisers LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at about $36,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Becton, Dickinson and Company by 378.9% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 182 shares of the medical instruments supplier’s stock valued at $42,000 after buying an additional 144 shares in the last quarter. Finally, Bank of Jackson Hole Trust grew its position in shares of Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 95 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Stifel Nicolaus decreased their target price on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research report on Friday. Piper Sandler decreased their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday. Jefferies Financial Group lowered their price objective on Becton, Dickinson and Company from $257.00 to $215.00 in a research report on Friday. Morgan Stanley upped their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $203.27.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,249 shares of company stock worth $231,358 over the last ninety days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $177.88 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The stock has a 50-day moving average of $186.77 and a two-hundred day moving average of $182.15. The stock has a market cap of $50.99 billion, a P/E ratio of 31.99, a P/E/G ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion during the quarter. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.4%. The ex-dividend date is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 71.36%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.